UPDATE - Barclays initiates coverage on Halozyme Therapeutics (Nasdaq: HALO) with an Overweight rating. PT $12.

Barclays analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE